ClinicalTrials.gg
CompletedNCT00634114Updated Jun 17, 2010Results posted

Reflux Esophagitis Phase III Study (Maintenance Treatment)

A Phase 3 interventional study of Esomeprazole and Esomeprazole in Reflux Esophagitis, sponsored by AstraZeneca. Completed at 44 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-06-17.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.

Started
2008
the only one that year
Phase 3
5 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is the only one that started in 2008, is one of 5 in phase 3, and was the 2nd registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →

Where they have run

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis, Peptic by AstraZeneca as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg once daily and esomeprazole 10 mg once daily by assessment of presence/absence of recurrence of Reflux Esophagitis throughout the treatment period (from the randomisation to the treatment completion) according to the Los Angeles classification.

03

Conditions studied

  • Reflux Esophagitis

Browse trials for

Keywords

  • Reflux Esophagitis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with healed Reflux Esophagitis verified by EGD in the preceding study (D961HC00002)
  • Patients with endoscopically verified healed Reflux Esophagitis by EGD receiving general treatment with PPI

Exclusion criteria

Exclusion Criteria:

  • Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation.
  • Use of any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (actual)

Study arms

  • Experimental
    1

    Esomeprazole and Omeprazole

    Drug: Esomeprazole · Drug: Omeprazole

  • Experimental
    2

    Esomeprazole

    Drug: Esomeprazole

Interventions

  • 10mg once daily oral administration

    Also known as: Nexium

  • 20mg once daily oral administration

    Also known as: Nexium

  • 10mg once daily oral administration

    Also known as: Prilosec

06

What researchers measure

Primary outcomes

  1. Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.

    Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D throughout the treatment period was evaluated.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment

    Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D up to 4 weeks after treatment was evaluated.

    Time frame: up to 4 weeks

  2. Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment

    Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D up to 12 weeks after treatment was evaluated.

    Time frame: Up to 12 weeks

07

Results

Posted Jun 17, 2010

Participant flow

Enrolment 8Jan08-19May09. 564 randomised participants, 563 in Full Analysis set and safety analysis set. FAS used for summaries of baseline characteristics and efficacy. SAS for summaries of safety. 1 pt. in Omep. 10 mg excluded as they took no investigational drug. Nos. for gender were 188 in Esom. 20 mg, 188 in Esom. 10 mg and 187 in Omep. 20 mg.

Participant flow — Overall Study
MilestoneExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
Started188189187
Completed160154148
Not completed283539
Withdrew: Adverse event683
Withdrew: Withdrawal by subject9611
Withdrew: Lost to follow-up001
Withdrew: Protocol violation331
Withdrew: Pregnancy100
Withdrew: Incorrect enrolment010
Withdrew: Recurrence of reflux esophagitis51521
Withdrew: Difficult to continue311
Withdrew: Other reason111

Outcome measures

SecondaryAbsence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment

Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D up to 4 weeks after treatment was evaluated.

Time frame:
up to 4 weeks
Reported as:
Number · Participants
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment
ParticipantsExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment184180171
PrimaryAbsence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.

Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D throughout the treatment period was evaluated.

Time frame:
Up to 24 weeks
Reported as:
Number · Participants
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.
ParticipantsExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.174166156
SecondaryAbsence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment

Los Angels classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). A patient classfied into Grade O was considered no reflux esophagitis. The participants who had a healing of reflux esophagitis with Grade O at Visit 1 were randomised. Number of participants who did not have Grades A-D up to 12 weeks after treatment was evaluated.

Time frame:
Up to 12 weeks
Reported as:
Number · Participants
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment
ParticipantsExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment179 (NA to NA)172 (NA to NA)163 (NA to NA)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Esomeprazole 20 mg—5/188 (2.7%)71/188 (37.8%)
Experimental: Esomeprazole 10 mg—4/188 (2.1%)69/188 (36.7%)
Comparator: Omeprazole 10 mg—1/187 (0.5%)34/187 (18.2%)
Most frequent serious events
Most frequent serious events
EventExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
ConstipationGastrointestinal disorders0/1880/1881/187
Colonic polypGastrointestinal disorders1/1881/1880/187
OesophagitisGastrointestinal disorders1/1880/1880/187
Hand fractureInjury, poisoning and procedural complications0/1881/1880/187
Subdural haematomaInjury, poisoning and procedural complications0/1881/1880/187
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1880/1880/187
Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1881/1880/187
TachyarrhythmiaCardiac disorders1/1880/1880/187
AsthmaRespiratory, thoracic and mediastinal disorders1/1880/1880/187
Most frequent other events
Showing 10 of 12
Most frequent other events
EventExperimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mg
NasopharyngitisInfections and infestations31/18837/18831/187
Abdominal pain upperGastrointestinal disorders11/1883/1884/187
DiarrhoeaGastrointestinal disorders4/1887/1887/187
Gastrooesophageal reflux diseaseGastrointestinal disorders2/1882/1885/187
Blood creatine phosphokinase increasedInvestigations5/1885/1882/187
Blood pressure increasedInvestigations1/1885/1881/187
ContusionInjury, poisoning and procedural complications5/1880/1882/187
ConstipationGastrointestinal disorders2/1881/1884/187
Abdominal distensionGastrointestinal disorders0/1880/1884/187
Upper respiratory tract infectionInfections and infestations4/1881/1880/187

Baseline characteristics

Age, Customized
Age, Customized(Participants)Experimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mgTotal
<65131 (131 to NA)131 (131 to NA)137 (137 to NA)399 (0 to 0)
65-7445 (45 to NA)41 (41 to NA)38 (38 to NA)124 (0 to 0)
>=7512 (12 to NA)16 (16 to NA)12 (12 to NA)40 (0 to 0)
Missing0 (0 to NA)1 (1 to NA)0 (0 to NA)1 (0 to 0)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Experimental: Esomeprazole 20 mgExperimental: Esomeprazole 10 mgComparator: Omeprazole 10 mgTotal
Female46 (142 to NA)51 (137 to NA)42 (145 to NA)139 (0 to 0)
Male142 (46 to NA)147 (51 to NA)145 (42 to NA)434 (0 to 0)
Missing0 (0 to NA)1 (1 to NA)0 (0 to NA)1 (0 to 0)
08

Study locations

44 sites
  • Research Site
    Kashiwa, Chiba, Japan
  • Research Site
    Kisarazu, Chiba, Japan
  • Research Site
    Koriyama, Fukishima, Japan
  • Research Site
    Nihonmatsu, Fukishima, Japan
  • Research Site
    Nishishirakawa, Fukishima, Japan
  • Research Site
    Fukuoika, Fukuoka, Japan
  • Research Site
    Kurume, Fukuoka, Japan
  • Research Site
    Nukaya, Fukuoka, Japan
  • Research Site
    Fukuoka, Fukuolka, Japan
  • Research Site
    Koriyama, Fukushima, Japan
  • Research Site
    Shirakawa, Fukushima, Japan
  • Research Site
    Sugawa, Fukushima, Japan
  • Research Site
    Gifu-shi, Gifu, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Yasunaka, Gunma, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Mito, Ibaraki, Japan
  • Research Site
    Tsukuba, Ibaraki, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Takamatsu, Kagawa, Japan
  • Research Site
    Fujisawa, Kanagawa, Japan
  • Research Site
    Kawasaki, Kanagawa, Japan
  • Research Site
    Sagamihara, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Shibata, Myagi, Japan
  • Research Site
    Kiso, Nagano, Japan
  • Research Site
    Matsumoto, Nagano, Japan
  • Research Site
    Fujiidera, Osaka, Japan
  • Research Site
    Toyonaka, Osaka, Japan
  • Research Site
    Ohtawara, Tochigi, Japan
  • Research Site
    Toshima-ku, Tokayo, Japan
  • Research Site
    Adachi, Tokyo, Japan
  • Research Site
    Hachioji, Tokyo, Japan
  • Research Site
    Kiyose, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Shinagawa, Tokyo, Japan
  • Research Site
    Shimonoseki, Yamaguchi, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Shizuoka, Japan
  • Research Site
    Tottori, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008 and a completion of May 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2008
First posted
Mar 12, 2008
Start
Jan 2008
CompletionActual
May 2009
Results first posted
Jun 17, 2010
Last update
Jun 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00634114
Lead sponsor
AstraZeneca
First posted
Mar 12, 2008
Start date
Jan 2008
Completion
May 2009
Results posted
Jun 17, 2010
Last update
Jun 17, 2010

Study contacts

Maotsugu Oyama, MD, PhD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion